Nature: SARS-CoV-2 variant evasion of monoclonal antibodies based on in vitro studies

A scientific paper looking at the future of monoclonal antibodies in treating Covid-19.

Authors: MacGregor Cox, Thomas P. Peacock, William T. Harvey, Joseph Hughes, Derek W. Wright, COVID-19 Genomics UK (COG-UK) Consortium, Brian J. Willett, Emma Thomson, Ravindra K. Gupta, Sharon J. Peacock, David L. Robertson & Alessandro M. Carabelli

Nature article: SARS-CoV-2 variant evasion of monoclonal antibodies based on in vitro studies

Nature: Immunological dysfunction persists for 8 months following initial mild-to-moderate…
Covid-19 is a leading cause of death in children and young people ages 0-19 years in the…
Unvaccinated staff to be reintegrated into Italian health service
Respiratory illness in dogs causing problems in Charlotte, NC
Sweden pauses Nuvaxovid, aka Novavax, for those under 31 years of age
Malaysia experiencing 'small' XBB wave

Coronaheadsup.com

The top pandemic stories from across the globe

Nature: SARS-CoV-2 variant evasion of monoclonal antibodies based on in vitro studies

Related Posts:

Contact Us